Characteristics of participants with virological failure at month 12.

A98G reduces NVP susceptibility, Y181C causes high-level resistance to NVP, G190A causes high level resistance to NVP and intermediate resistance to EFV, M184V cause high-level in vitro resistance to 3TC, K103N causes high-level resistance to NVP, and EFV, D67N, K70R and K219Q cause resistance to AZT and d4T. *These participants showed mutations at baseline (see table 2). **Participant sample failed sequencing at baseline. NA- Not applicable since these samples failed to sequence at both baseline and month 12. The drugs in bold and underlined have a reduced sensitivity against the mutated viruses.